Metagenomi Inc is a pioneering biotech firm based in Emeryville, California, focusing on developing groundbreaking gene editing therapies. Leveraging a comprehensive suite of genome editing tools, including advanced nucleases and base editors, the company aims to revolutionize treatments for various diseases. Through strategic partnerships with industry leaders like ModernaTX and Affini-T Therapeutics, Metagenomi is at the forefront of creating innovative solutions for in vivo human therapies and cancer treatment. Founded in 2016, its commitment to leveraging metagenomics-derived technologies positions it as a key player in the biotechnology sector.
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
